BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Citi maintains buy on Aurobindo Pharma
Company has good visibility on medium-term growth. Company is getting stronger in the US. Balance sheet to improve further as debt comes down.